Skip to content
10-K

Annual Report

BICARA THERAPEUTICS INC. BCAX

0002023658-25-000012

← back to feed
Filed
Mar 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 24, 2025 54.52M sh
Rd Expense FY 2024 · Dec 31, 2024 $63.6M
Rd Expense FY 2024 · Dec 31, 2023 $30.6M
Shares Diluted FY 2024 · Dec 31, 2023 580.11M sh
Capex FY 2024 · Dec 31, 2023 $586K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$45.63M
Cash And Equivalents FY 2024 · Dec 31, 2023 $230.44M
Current Liabilities FY 2024 · Dec 31, 2023 $15.09M
Total Liabilities FY 2024 · Dec 31, 2023 $15.47M
Current Assets FY 2024 · Dec 31, 2023 $231.07M
Total Assets FY 2024 · Dec 31, 2023 $233.98M
Eps Diluted FY 2024 · Dec 31, 2023 −$89.61
Eps Basic FY 2024 · Dec 31, 2023 −$89.61
Sga Expense FY 2024 · Dec 31, 2023 $9.27M
Net Income FY 2024 · Dec 31, 2023 −$51.99M
Operating Income FY 2024 · Dec 31, 2023 −$39.89M
Stockholders Equity FY 2024 · Dec 31, 2022 −$98.8M